Court Dismisses Endo Suit, Opens Door to Generic Opana ER

A Washington, D.C., district court judge has thrown out Endo Pharmaceuticals’ bid to prevent generic companies from producing the opioid drug Opana ER. In March, the company pulled its oxymorphone extended-release drug off the shelves and replaced it with a new formulation it says is crush-resistant and harder to snort.
Generic Line